MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Exact Sciences Set to Acquire Biomatrica

The Madison, WI-based company said it intends use Biomatrica’s technology to support ongoing and future development of its own blood-based cancer detection tests.

Medtech acquisitions remain fast and furious today as Exact Sciences is acquiring sample preservation specialist Biomatrica. The deal between the two is for an undisclosed sum.

San Diego-based Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences said it intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.

"To detect cancer at its earliest stages, you need the right team backed by the highest-quality science, data and materials," Kevin Conroy, chairman and CEO of Exact Science said in a release. "Biomatrica's preservation chemistry ensures the reliability of results, even when blood and other biological samples undergo the stresses of shipping and storage."

Established in 2005, Biomatrica holds eight issued U.S. utility patents, one issued U.S. design patent, and 36 issued patents in foreign jurisdictions.

Four additional patents are pending in the U.S. These patents pertain to technologies that stabilize biological materials. Under the terms of the acquisition, Biomatrica will operate as a wholly owned subsidiary of Exact Sciences and will continue to supply tubes and sample preservation technologies to other companies.

This marks the second Thursday medtech deal. Another was between Getinge’s subsidiary, Atrium Medical and HJ Capital 1, the parent company of SeCQure Surgical. Under the deal, HJ Capital 1, would acquire Atrium’s biosurgery business for an undisclosed sum.

Filed Under
500 characters remaining